TGA approves Foundayo, first daily GLP-1 weight loss pill, available within days
The TGA approved Foundayo, a daily GLP-1 pill that works like Ozempic without injections.
Reported by PerthNowAlso reported by The Nightly, 7NEWS.Claims checked against the source, 6 h ago.
ShareWhy it matters
A simpler GLP-1 option means more Australians may be able to treat obesity and type 2 diabetes, though cost could limit access until the government subsidises it.
In Australia. Australians can now access an oral GLP-1 without injections, though the high private cost means wealthy patients benefit first; PBS listing would expand access.
Key facts
- 13 million
- Australians affected by obesity
- at least 30
- Serious diseases linked to obesity
- more than 10,000
- Clinical trial participants
- 15
- Countries in trial
- The Therapeutic Goods Administration cleared Foundayo on Tuesday, a daily pill that mimics a natural hormone to control hunger and slow digestion, the same action as Ozempic and Wegovy.
- Lilly said it can be taken any time of day with no meal or water requirement.
- The drug is available now through private prescription but has not yet been added to the Pharmaceutical Benefits Scheme, which would make it cheaper.
- Around 13 million Australians deal with overweight or obesity, which raises the risk of at least 30 serious diseases including cancer and heart disease.
- Lilly's clinical trials involved more than 10,000 patients across 15 countries, including Australian hospitals.


